Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia

Am J Trop Med Hyg. 2001 Oct;65(4):309-17. doi: 10.4269/ajtmh.2001.65.309.

Abstract

Combining artesunate with existing antimalarial drugs may improve cure rates, delay emergence of resistance, and reduce transmission. We performed a randomized comparative trial to quantify the effect of adding artesunate to sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria in Indonesia. Using a modified 1997 World Health Organization protocol for assessment of therapeutic efficacy of antimalarial drugs, 105 patients (stratified by age/ethnic group) were randomized: 53 received artesunate orally, 4 mg/kg of body weight, a single daily dose for three days, plus sulfadoxine-pyrimethamine orally (1.25 mg of pyrimethamine/kg of body weight), a single dose on day 0, and 52 patients received sulfadoxine-pyrimethamine alone. Six from the combination group were withdrawn from analysis, as were six of the sulfadoxine-pyrimethamine group. Treatment failure rates on day 14 were 0% in the artesunate plus sulfadoxine-pyrimethamine group and 8.7% in the sulfadoxine-pyrimethamine group (P = 0.12). Treatment failure rates on day 28 were 4.4% and 15.2%, respectively (P = 0.16). Relative risk of treatment failure at 28 days was 0.3 (95% confidence interval [CI] = 0.1-1.3). Mean fever clearance time (1.3 versus 1.7 days) and mean parasite clearance time (1.4 versus 2.0 days) were both faster in the artesunate plus sulfadoxine-pyrimethamine group than in the sulfadoxine-pyrimethamine group (P = 0.08 and P < 0.0001, respectively). Only 20 (39.2%) of 51 patients treated with artesunate plus sulfadoxine-pyrimethamine were still parasitemic on day 1 compared with 45 (86.5%) of 52 patients treated with sulfadoxine-pyrimethamine alone (P = 0.000001, relative risk [RR] = 0.4, 95% CI = 0.3-0.6). Gametocyte carriage was lower following artesunate plus sulfadoxine-pyrimethamine than following sulfadoxine-pyrimethamine (RR = 0.5, 95% CI = 0.2-1.0 on day 7 and RR = 0.5, 95% CI = 0.2-1.1 on day 14). Mild diarrhea, rash, and itching resolved without treatment. Combined artesunate plus sulfadoxine-pyrimethamine resulted in more rapid fever and parasiteclearance, was well tolerated, reduced risk of treatment failure, and lowered gametocyte carriage.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Antimalarials / pharmacology
  • Antimalarials / therapeutic use*
  • Artemisinins*
  • Artesunate
  • Child
  • Child, Preschool
  • Drug Combinations
  • Drug Resistance
  • Drug Therapy, Combination
  • Female
  • Fever
  • Humans
  • Indonesia
  • Infant
  • Malaria, Falciparum / drug therapy*
  • Malaria, Falciparum / physiopathology
  • Male
  • Middle Aged
  • Parasite Egg Count
  • Parasitemia / drug therapy
  • Parasitemia / physiopathology
  • Parasitic Sensitivity Tests
  • Plasmodium falciparum / drug effects*
  • Pyrimethamine / pharmacology
  • Pyrimethamine / therapeutic use*
  • Risk
  • Sesquiterpenes / pharmacology
  • Sesquiterpenes / therapeutic use*
  • Sulfadoxine / pharmacology
  • Sulfadoxine / therapeutic use*
  • Time Factors
  • Treatment Failure
  • Treatment Outcome

Substances

  • Antimalarials
  • Artemisinins
  • Drug Combinations
  • Sesquiterpenes
  • fanasil, pyrimethamine drug combination
  • Artesunate
  • Sulfadoxine
  • Pyrimethamine